Ptosis: Evaluation and management

Pauly, Marian; Sruthi, R

doi:10.4103/kjo.kjo_2_19

Cited by 20 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Curcumin may increase the gene expression of GHR and may cause an elevation in ligand sensitivity to GH-induced IGF production in muscle. The upregulation of IGF genes in muscle may result in an increase in growth parameters as indicated by the increased total weight gain (TWG, g), specific growth rate (SGR, %) and reduced feed conversion rate (FCR, kg/kg) as reported in our earlier findings Sruthi (2019).…”

Section: Discussionsupporting

confidence: 58%

Curcumin in diet modulates fatty acid levels and mRNA expression of appetite‐regulating neuropeptides in brain and enhances growth via the GH‐GHR‐IGF axis in tilapia, Oreochromis mossambicus

Sruthi

Lekha

2023

Journal of Fish Biology

View full text Add to dashboard Cite

Curcumin in 0.5% and 1% doses was given as a feed additive to tilapia (Oreochromis mossambicus) for 100 days to evaluate the effect of curcumin on fatty acid levels in brain, appetite and the growth axis‐related gene expressions. A total of 180 fish were randomly stocked into 650 l tanks and fed with basal feed during acclimatization. Three treatment groups were established, each having three replicates and each replicate had 20 fish. They were fed twice on the experimental diets of 10% body weight ration per fish. Gas chromatography analysis revealed a significant change in the amount of total saturated fatty acids and total monounsaturated fatty acids in tilapia brain. The present study indicated an increase in n‐3 (omega‐3) and n‐6 (omega‐6) polyunsaturated fatty acids in brain. Real‐time quantification of appetite‐regulating neuropeptides in brain and growth‐related gene expressions in muscle revealed a significant modulation in their mRNA expressions. This information obtained in the present study on the beneficial role of curcumin in the regulation of fatty acid levels and the expression of appetite‐regulating neuropeptides and growth‐regulating factors will contribute to research in feed intake and growth in fish.

show abstract

Section: Discussionsupporting

confidence: 58%

Curcumin in diet modulates fatty acid levels and mRNA expression of appetite‐regulating neuropeptides in brain and enhances growth via the GH‐GHR‐IGF axis in tilapia, Oreochromis mossambicus

Sruthi

Lekha

2023

Journal of Fish Biology

View full text Add to dashboard Cite

show abstract

“…In general, it is categorized into classes according to the fundamental pathogenesis: aponeurotic, myogenic, neurogenic, mechanical, and traumatic. Within these classifications, there are further subdivisions to aid diagnosis and management according to whether the blepharoptosis is congenital or acquired, on one side or on both sides, isolated or as a part of a syndrome, or symptomatically driven by aesthetic or functional deficits [1][2][3] .…”

Section: Introductionmentioning

confidence: 99%

Natural and synthetic materials for frontalis suspension in severe congenital ptosis (Comparative study)

EL-Najar

Metwally²,

Elghfar³

et al. 2022

Egyptian Journal of Ophthalmology, (Mansoura Ophthalmic Center)

View full text Add to dashboard Cite

Purpose: To compare a variety of materials that were used in frontalis suspension surgery for correction of severe congenital ptosis. Treating severe congenital ptosis can be challenging and a proper preoperative evaluation may help prevent unexpected outcomes. Patients and method:This study included 60 patients suffering from severe congenital ptosis, patients will be randomizelly allocated in two equal interventional groups: First group (38 eye included) underwent FS ptosis surgery using Fascia lata and the second group (70 eye included) underwent FS ptosis surgery using synthetic material Results: at the end of the follow-up period (6 months postoperatively), most of the patients in both groups (89.5% of group A, 75.7% of group B) achieved good to excellent cosmetic results. Conclusion:considering the use of the Facia lata sling material and Synthetic material, Using Crawford technique were both safe and effective with comparable results in the correction of severe ptosis with poor levator Function.

show abstract

“…[13][14][15] The standard of care for acquired blepharoptosis is surgical intervention targeting the levator, Müller's muscle, and levator aponeurosis. 5,16,17 Surgery is effective in improving eyelid elevation, superior visual field function, and quality-of-life measures, 16,[18][19][20] but it also presents complication risks. These range from short-term concerns (bleeding, swelling, infection) that typically heal in the weeks post-procedure, to more persistent complications (lagophthalmos, exposure keratopathy) requiring further intervention.…”

Section: Introductionmentioning

confidence: 99%

Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials

Wirta¹,

Korenfeld²,

Foster³

et al. 2021

OPTH

View full text Add to dashboard Cite

Purpose: An oxymetazoline 0.1% ophthalmic solution was recently approved for treatment of acquired blepharoptosis in adults. This study's objective was to evaluate the safety profile of oxymetazoline 0.1% when administered once daily for 14-84 days. Patients and Methods: Pooled analysis examined safety outcomes from four randomized, double-masked, placebo-controlled clinical trials conducted at 6, 16, 27, and 35 sites, respectively, in the United States. In total, 568 participants with acquired blepharoptosis were evaluated. Median age was 66 years and 74.8% of participants were female. Overall, 375 participants self-administered oxymetazoline 0.1% to both eyes once/day and 193 self-administered placebo (vehicle) daily. Treatment-emergent adverse event (TEAE) rates, severity, and causality were evaluated in the overall population and within participant subgroups defined based on age, race, and ethnicity. Vital signs and ophthalmic findings were evaluated at predefined study visits. Patient-reported treatment tolerability was recorded at study end. Results: TEAE incidence was similar among participants using oxymetazoline 0.1% (31.2%) or vehicle (30.6%). Nearly all TEAEs were mild-to-moderate, and most were not suspected of being treatment related. Serious TEAEs occurred in four participants receiving oxymetazoline 0.1% and one participant receiving vehicle. Nine and two participants in the oxymetazoline 0.1% and vehicle groups, respectively, discontinued due to a TEAE. Ocular TEAEs occurring in ≥2% of participants receiving oxymetazoline 0.1% were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, and corneal vital dye staining, with none occurring in >3.5% of participants. TEAE rates were similar across subgroups based on age, race, and ethnicity. No clinically significant mean changes in vital signs or ophthalmologic findings occurred, and >98% of participants rated oxymetazoline 0.1% as causing no/mild discomfort. Conclusion: Once-daily oxymetazoline 0.1% was safe and well tolerated in participants with acquired blepharoptosis when used for 14-84 days. Safety did not appear to differ based on age, race, or ethnicity.

show abstract

Ptosis: Evaluation and management

Cited by 20 publications

References 0 publications

Curcumin in diet modulates fatty acid levels and mRNA expression of appetite‐regulating neuropeptides in brain and enhances growth via the GH‐GHR‐IGF axis in tilapia, Oreochromis mossambicus

Curcumin in diet modulates fatty acid levels and mRNA expression of appetite‐regulating neuropeptides in brain and enhances growth via the GH‐GHR‐IGF axis in tilapia, Oreochromis mossambicus

Natural and synthetic materials for frontalis suspension in severe congenital ptosis (Comparative study)

Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials

Contact Info

Product

Resources

About